AVNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avanos Medical Inc (AVNS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, the financial performance is weak, and there are no significant positive catalysts or trading signals to suggest an immediate entry point. Holding off for now is advisable.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 40.799, and moving averages are converging, showing no clear trend. Support and resistance levels are close to the current price, with the stock trading near the pivot point of 13.486.
Barclays raised the price target for a related company, Aveanna, which may suggest some confidence in the broader sector.
Purcell & Lefkowitz LLP is investigating Avanos Medical for potential breaches of fiduciary duties, which could negatively impact investor sentiment. Additionally, the company's financial performance in Q4 2025 showed a significant drop in net income (-99.67% YoY) and EPS (-99.65% YoY).
In Q4 2025, revenue increased slightly by 0.72% YoY to $180.9M. However, net income dropped drastically to -$1.3M (-99.67% YoY), and EPS fell to -0.03 (-99.65% YoY). Gross margin also declined to 47.54%, down 12.88% YoY.
No recent analyst updates for Avanos Medical Inc. However, Barclays raised the price target for Aveanna, a related company, to $11 from $9, maintaining an Overweight rating.
